Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
LDH
NLR
immune checkpoint inhibitors
ocular melanoma
prognosis
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
04
10
2022
revised:
21
11
2022
accepted:
22
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Background: There is no standardized treatment for metastatic uveal melanoma (MUM) but immune checkpoint inhibitors (ICI) are increasingly used. While ICI has transformed the survival of metastatic cutaneous melanoma, MUM patients do not equally benefit. Factors known to affect ICI response include the hematologic markers, lactate dehydrogenase (LDH) and neutrophil:lymphocyte ratio (NLR). We evaluated the prognostic value of LDH and NLR at the start of ICI and on treatment in MUM. Methods: MUM patients were treated between August 2006 and May 2022 with combination ipilimumab/nivolumab or ipilimumab/nivolumab/pembrolizumab single-agent therapy. Univariable (UVA) and multivariable (MVA) analyses were used to assess the prognostic value of predefined baseline factors on progression-free (PFS) and overall survival (OS). Results: In forty-six patients with MUM treated with ICI, elevated baseline and on-treatment LDH was prognostic for OS (start of ICI, HR (95% CI): 3.6 (1.9−7.0), p < 0.01; on-treatment, HR (95% CI): 3.7 (1.6−8.8), p < 0.01) and PFS (start of ICI, (HR (95% CI): 2.8 (1.5−5.4), p < 0.0001); on-treatment LDH (HR (95% CI): 2.2 (1.1−4.3), p < 0.01). On-treatment NLR was prognostic for PFS (HR (95% CI): 1.9 (1.0−3.9), p < 0.01). On-treatment LDH remained an important contributor to survival on MVA (OS: HR (95% CI): 1.001 (1.00−1.002), p < 0.05); PFS: HR (95% CI): 1.001 (1.00−1.002), p < 0.01). Conclusions: This study demonstrates that LDH and NLR could be useful in the prognostication of MUM patients treated with ICI. Additional studies are needed to confirm the importance of these and other prognostic biomarkers.
Identifiants
pubmed: 36497270
pii: cancers14235789
doi: 10.3390/cancers14235789
pmc: PMC9738244
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Scientist Training program
ID : GM007863
Organisme : University of Michigan Rackham Merit Fellowship
ID : na
Organisme : Lung Precision Oncology Program
ID : VA 150CU000182
Organisme : LUNGevity, Breast Cancer Research Foundation, Melanoma Research Alliance
ID : MRA689853
Organisme : BLRD VA
ID : I01 BX005267
Pays : United States
Organisme : NCI NIH HHS
ID : CA252010
Pays : United States
Organisme : Richard N and Marilyn K Witham professorship
ID : na
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 2016 Mar 15;114(6):612-5
pubmed: 26889974
Cancer. 2020 Jan 1;126(1):76-85
pubmed: 31584709
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824580
Oncotarget. 2018 Jun 22;9(48):28903-28909
pubmed: 29988983
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Mayo Clin Proc. 2011 Oct;86(10):981-90
pubmed: 21964175
Cancer Immunol Immunother. 2022 Jun;71(6):1467-1477
pubmed: 34709438
Nat Commun. 2018 May 14;9(1):1866
pubmed: 29760383
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922591
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735
Cancers (Basel). 2019 Oct 03;11(10):
pubmed: 31623302
Clin Cancer Res. 2016 Mar 1;22(5):1234-42
pubmed: 26933176
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33262254
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
JAMA Netw Open. 2021 Mar 1;4(3):e210980
pubmed: 33687443
Oncology (Williston Park). 2018 Sep 18;32(9):e90-e96
pubmed: 30248170
Eur J Surg Oncol. 2009 Nov;35(11):1192-7
pubmed: 19329272
Cancers (Basel). 2021 Nov 13;13(22):
pubmed: 34830841
Melanoma Res. 2018 Dec;28(6):571-577
pubmed: 30067547
Medicine (Baltimore). 2021 Apr 9;100(14):e25318
pubmed: 33832106
JAMA. 2014 Jun 18;311(23):2397-405
pubmed: 24938562
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Immunol Immunother. 2014 Jul;63(7):675-83
pubmed: 24695951
Lung Cancer. 2022 Jan;163:35-41
pubmed: 34896803
Cancers (Basel). 2021 Jul 08;13(14):
pubmed: 34298647
Arch Ophthalmol. 2001 May;119(5):670-6
pubmed: 11346394
Nat Commun. 2021 Aug 27;12(1):5155
pubmed: 34453044
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
Ophthalmology. 1988 Jul;95(7):1000-4
pubmed: 3174030
HPB (Oxford). 2020 Apr;22(4):497-505
pubmed: 31791894
J Clin Oncol. 2021 Feb 20;39(6):586-598
pubmed: 33417511
Ophthalmol Sci. 2022 Jan 24;2(2):100117
pubmed: 36249686
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Prog Retin Eye Res. 2022 Sep;90:101041
pubmed: 34999237
BMC Cancer. 2019 Aug 29;19(1):857
pubmed: 31464611
Cell. 2013 Jun 6;153(6):1239-51
pubmed: 23746840
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209601
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581057
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Cancer Med. 2018 Dec;7(12):6124-6136
pubmed: 30403008
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Cancers (Basel). 2019 Jun 18;11(6):
pubmed: 31216772
J Clin Oncol. 2005 Nov 1;23(31):8076-80
pubmed: 16258106
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185
pubmed: 31175402
J Clin Oncol. 2021 Feb 20;39(6):599-607
pubmed: 33125309
Br J Cancer. 2017 Apr 25;116(9):1141-1147
pubmed: 28324889
Br J Ophthalmol. 2017 Jan;101(1):38-44
pubmed: 27574175
ESMO Open. 2019 Aug 16;4(4):e000531
pubmed: 31555483
Clin Cancer Res. 2019 Oct 1;25(19):5735-5742
pubmed: 30992297
J Immunol. 2013 Aug 1;191(3):1486-95
pubmed: 23817426
Br J Cancer. 2015 Jun 9;112(12):1904-10
pubmed: 26010413
Eur J Cancer. 2022 Sep;173:105-112
pubmed: 35863105